Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a Danish specialty pharmaceutical company focused on improving the delivery and clinical usability of difficult-to-formulate medicines. The company originated in 2002 as a spin-off from H. Lundbeck A/S and was initially known as LifeCycle Pharma A/S. Its business model centered on proprietary formulation science rather than the discovery of entirely new chemical entities. The principal platform was MeltDose, a technology designed to improve the dissolution and absorption of drugs with poor water solubility. MeltDose combines an active pharmaceutical ingredient with a meltable carrier and deposits the resulting material onto an inert particulate carrier using fluid-bed processing. The process creates a solid dispersion or nanocrystalline form of the drug, after which the material can be converted into tablets. By controlling particle size, processing conditions, and release characteristics, the platform was intended to produce stable oral formulations with improved bioavailability, consistent dissolution, and potentially more convenient dosing. The technology could also be adapted to different release profiles and was designed to support long shelf life. Veloxis shifted its strategic emphasis toward transplant medicine, particularly tacrolimus, an immunosuppressant used to prevent rejection after organ transplantation. Its leading product candidate, LCP-Tacro, was developed as a once-daily formulation of tacrolimus, in contrast with conventional twice-daily products such as Prograf. Clinical development included Phase 3 studies in kidney-transplant recipients. Results from a study in stable transplant patients indicated that the once-daily formulation was non-inferior to twice-daily tacrolimus for efficacy and safety. A later Phase 3b study examined whether patients with symptomatic tremor associated with twice-daily tacrolimus could experience improvement after switching formulations. The product received United States regulatory approval in 2015 under the brand name Envarsus XR. It became the company’s principal commercial product and represented the practical application of the MeltDose platform in a high-value, specialist pharmaceutical market. Envarsus XR is an extended-release tacrolimus tablet used for prophylaxis of organ rejection in kidney-transplant recipients in combination with other immunosuppressants. Because tacrolimus has a narrow therapeutic index and exposure can vary substantially among patients, formulation and dosing consistency are important considerations in transplant care. Veloxis also developed and commercialized other formulation-based products. Fenofibrate product Fenoglide was marketed in the United States by Santarus for dyslipidemia. However, transplant immunosuppression became the central focus of the company’s commercial identity and corporate strategy. Veloxis maintained its headquarters in Hørsholm, Denmark, and established a United States office in Cary, North Carolina, reflecting its orientation toward the American pharmaceutical and transplant market. In 2020, Asahi Kasei Corporation completed the acquisition of Veloxis. The transaction ended Veloxis’s period as an independent public pharmaceutical company and placed its transplant medicine business within Asahi Kasei’s healthcare portfolio. Veloxis is therefore best understood today as an acquired specialty-pharmaceutical business and product organization rather than as a standalone listed company. Its historical significance lies in the commercialization of a differentiated tacrolimus formulation and in the application of MeltDose technology to medicines whose absorption and formulation present technical challenges.

Veloxis Pharmaceuticals began in 2002 as a spin-off from Danish pharmaceutical company H. Lundbeck A/S. It was originally established under the name LifeCycle Pharma A/S and developed a business around pharmaceutical formulation technology. Rather than concentrating primarily on novel molecular discovery, the company sought to create improved versions of existing medicines whose clinical performance could be affected by low solubility, variable absorption, or inconvenient dosing schedules. The company’s central technical asset was MeltDose. In this process, a poorly water-soluble active ingredient is incorporated into a meltable vehicle and sprayed onto an inert particulate carrier in a fluid-bed system. As the material solidifies, the active ingredient is captured in a solid dispersion or nanocrystalline form. The resulting granulate can be blended and compressed into tablets, while processing parameters can be adjusted to influence particle size and drug release. The technology was intended to preserve dissolution characteristics during storage and to support formulations with stable performance and long shelf life. LifeCycle Pharma later changed its name to Veloxis Pharmaceuticals as it developed a more focused specialty-pharmaceutical strategy. The company concentrated its clinical and commercial efforts on transplant medicine, especially tacrolimus. Tacrolimus is widely used to suppress immune responses after organ transplantation, but it has a narrow therapeutic index and is commonly administered more than once per day. Veloxis developed LCP-Tacro, a once-daily formulation intended to provide an alternative delivery profile to conventional twice-daily tacrolimus products. Clinical development included two major Phase 3 studies in kidney-transplant patients. In stable transplant recipients, LCP-Tacro demonstrated non-inferior efficacy and safety compared with twice-daily tacrolimus. A further study examined patients who had recently received transplants, while a Phase 3b program investigated whether switching patients with tacrolimus-associated symptomatic tremor to the once-daily formulation could improve tremor-related and other patient-reported outcomes. These studies supported the company’s effort to differentiate its product through dosing convenience and formulation characteristics rather than through a new immunosuppressive mechanism. The U.S. Food and Drug Administration approved the product in 2015 under the name Envarsus XR. It became Veloxis’s principal commercial product and the most important application of MeltDose technology. The product was positioned for kidney-transplant recipients and used with other immunosuppressive medicines. Veloxis also had experience with other formulation-based products, including Fenoglide, a fenofibrate product marketed in the United States by Santarus for dyslipidemia. Veloxis maintained its corporate headquarters in Hørsholm, Denmark, and operated a U.S. office in Cary, North Carolina. The United States was particularly important because it was the primary market for Envarsus XR and the location of much of the company’s commercial and regulatory activity. The company’s history therefore combined Danish pharmaceutical research and corporate origins with a commercially focused U.S. specialty-drug strategy. Asahi Kasei announced an agreement to acquire Veloxis and completed the transaction in 2020. The acquisition ended Veloxis’s independent corporate existence as a public pharmaceutical company and integrated its business into Asahi Kasei’s healthcare operations. The Veloxis name remains associated with the formulation technology, the development of once-daily tacrolimus, and the Envarsus XR product, while ownership and strategic control reside with Asahi Kasei.

• 2020

  Acquired by Asahi Kasei

  [1]Veloxis Pharmaceuticalsen.wikipedia.org

  Asahi Kasei completed the acquisition of Veloxis, ending the company’s independence as a standalone listed pharmaceutical business.

• 2017

  Phase 3b tremor study published

  [1]Veloxis Pharmaceuticalsen.wikipedia.org

  Clinical results examined patient-reported outcomes after transplant patients with symptomatic tremor switched to LCP-Tacro.

• 2015

  Envarsus XR approved in the United States

  [1]Veloxis Pharmaceuticalsen.wikipedia.org

  The company’s once-daily tacrolimus formulation received U.S. approval for prevention of organ rejection in kidney-transplant recipients.

• 2008

  Renamed Veloxis Pharmaceuticals

  [1]Veloxis Pharmaceuticalsen.wikipedia.org

  LifeCycle Pharma adopted the Veloxis Pharmaceuticals name as it developed its specialty-pharmaceutical strategy.

• 2002

  Founded as a Lundbeck spin-off

  [1]Veloxis Pharmaceuticalsen.wikipedia.org

  The company was established as a spin-off from H. Lundbeck A/S under the name LifeCycle Pharma A/S.

A specialty pharmaceutical developer focused on differentiated formulations of difficult-to-formulate medicines, with particular emphasis on transplant immunosuppression and tacrolimus delivery.

• Drug formulation technology

  MeltDose

  MeltDose is Veloxis’s proprietary formulation platform for active ingredients with low water solubility. It uses a meltable carrier and fluid-bed processing to create a solid dispersion or nanocrystalline form on particulate material. The resulting granulate can be compressed into tablets and can be engineered for a selected release profile. The platform was intended to improve dissolution, support more consistent oral absorption, and maintain stable product characteristics during storage.

• Transplant immunosuppressant development candidate

  LCP-Tacro

  LCP-Tacro was Veloxis’s once-daily formulation of tacrolimus for prevention of organ-transplant rejection. It was studied in kidney-transplant patients in Phase 3 programs, including comparisons with twice-daily tacrolimus and a study of patients experiencing symptomatic tremor. The formulation was designed to apply MeltDose technology to a drug requiring careful exposure management and regular therapeutic monitoring.

• Extended-release tacrolimus · 2015

  Envarsus XR

  Envarsus XR is an extended-release tacrolimus tablet developed from LCP-Tacro and approved in the United States in 2015. It is used with other immunosuppressants to prevent organ rejection in kidney-transplant recipients. Its principal differentiation is once-daily administration and the modified-release formulation produced using Veloxis’s delivery technology.

• Fenofibrate

  Fenoglide

  Fenoglide is a fenofibrate formulation for dyslipidemia. It represented an earlier application of Veloxis’s formulation-oriented business model and was marketed in the United States by Santarus. The product addressed lipid disorders rather than transplant immunosuppression.

• 2020

  Accept acquisition by Asahi KaseiM&A

  Background

  Veloxis had developed a commercially established transplant product but remained a relatively focused specialty-pharmaceutical company with Danish origins and significant U.S. market exposure.

  Action taken

  Asahi Kasei completed the acquisition of Veloxis Pharmaceuticals.

  Aftermath

  Veloxis ceased to operate as an independent listed company and its business became part of Asahi Kasei’s healthcare portfolio.

  Source

• 2015

  Commercialize once-daily tacrolimus as Envarsus XRProduct launch

  Background

  Veloxis had built its clinical and corporate strategy around LCP-Tacro, a modified-release tacrolimus formulation intended to address dosing convenience and formulation-related differences in transplant immunosuppression.

  Action taken

  Following U.S. regulatory approval, the company brought the product to market under the Envarsus XR name for kidney-transplant recipients.

  Aftermath

  Envarsus XR became Veloxis’s principal commercial product and its most visible application of MeltDose technology.

  Source

• 2021-09-08

  Xenikos closes €40 million convertible debt financing[2]Xenikos 完成 4000 万欧元可转换债务融资finanznachrichten.de

  Reported: 2021-09-08

  Xenikos announced the closing of €40 million in convertible debt financing, led by Veloxis Pharmaceuticals, with participation from existing investors. In connection with the financing, Veloxis was to obtain two sequential call options to acquire Xenikos and a board seat.

1. 1Veloxis Pharmaceuticalsen.wikipedia.org
2. 2Xenikos 完成 4000 万欧元可转换债务融资finanznachrichten.de